Aptevo expands oncology pipeline with two new trispecific candidates APVO452 and APVO451

Aptevo Therapeutics Inc.

Filed provisional patents for APVO452 (PSMA x CD3 x CD40) targeting prostate cancer and APVO451 (Nectin-4 x CD3 x CD40) for multiple solid tumors.
Trispecific design engages tumor antigen, T cells, and immunosuppressive cells via ADAPTIR-FLEX platform to modulate tumor microenvironment.
Mipletamig clinical validation: >100 patients treated with high remission rates and no observed cytokine release syndrome in frontline AML.
Pipeline now includes 8 bispecific/trispecific candidates; 5 employ CRIS-7-derived CD3 binding domain for improved safety.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.